One of the most detailed maps ever of meningioma, the most common brain tumor in adults, reveals how the environment around a tumor helps drive disease behavior and patient outcomes, according to a new Mayo Clinic study.
This study natural genetics The study, conducted in collaboration with scientists at Toronto’s Princess Margaret Cancer Center, combines several advanced testing techniques to examine tumors at an unprecedented level of detail, providing clues as to why some meningiomas grow slowly, while others recur or become more malignant. This discovery could lead to more accurate ways to predict risk and decide on treatments.
Increasing evidence indicates that traditional meningioma grading systems do not fully capture the behavior of these complex tumors, prompting the development of molecular classification tools that more accurately predict which tumors are more likely to recur after surgery. These new findings build on recent developments by examining signals from individual cells rather than the entire tumor, demonstrating that the tumor microenvironment – the mixture of immune and supporting cells surrounding the tumor – plays a critical role in shaping outcome.
We are now learning that it is not just the tumor cells themselves, but the ecosystem around them that influences how these tumors grow and respond to treatment. ”
Gelareh Zadeh, MD, Ph.D., Mayo Clinic Neurosurgeon, study senior author
Understanding tumor behavior
An estimated 30,000 to 40,000 people are diagnosed with meningioma each year in the United States. Although many tumors are benign, predicting the risk of recurrence remains a major challenge as others are recurrent or life-threatening.
In this study, the researchers analyzed hundreds of tumor samples using a technique that allows them to study individual cells rather than averaging the signal across the tumor. The research team used single-cell sequencing and spatial transcriptomics to map millions of data points across more than 500,000 individual cells and entire tumors. This creates a high-resolution “atlas” of the genetic footprint of individual cells, showing how they differ between malignant and benign tumors, how they change and evolve in space, and how they interact with other cells in the environment.
“Instead of looking at the tumor as a whole, we can now break it down into its individual components and understand what is causing the tumor to behave,” says Dr. Zadeh.
Researchers have identified multiple distinct states of immune cells, particularly myeloid cells, that behave differently depending on the tumor. Some of these cellular states are associated with more aggressive disease, while others are associated with better outcomes.
Impact on patient care
This discovery builds on previous work by Mayo Clinic researchers that outlined a new era of personalized care for meningioma, where molecular and cellular insights guide clinical decision-making. This latest study added an important layer by showing how the tumor microenvironment contributes to its individualization.
Researchers have found that specific immune cell programs are strongly associated with the rate of tumor recurrence after treatment. In some cases, these signals can add value to tumor grade and modern molecular classification systems in their ability to predict patient outcome, suggesting that they may help refine decisions regarding future surgery, radiation, or closer follow-up.
The study also shows that these biological signatures may be detectable through non-invasive approaches such as blood-based biomarkers, raising the possibility of monitoring patients over time without repeat surgery.
“This brings us closer to a future where we can better stratify patients and identify those who need more aggressive treatment and those who can avoid overtreatment,” Dr. Zadeh says.
In addition to improving prognostic tools, this study also revealed potential therapeutic targets. By identifying how immune cells and tumor cells communicate, the study points to pathways that could be inhibited to slow tumor growth or increase treatment response.
Next steps include validating the results in large multicenter cohorts and translating these biological insights into clinical tools and prospective trials.
sauce:
Reference magazines:
Landry, AP; others. (2026). Spatially resolved single-cell analysis of human meningiomas identifies novel cellular states that influence tumor microenvironment and progression. natural genetics. DOI: 10.1038/s41588-026-02615-w. https://www.nature.com/articles/s41588-026-02615-w
